InceptionR’s Novavax NVAX Stock Holding History

InceptionR’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,410	Closed	-$169K	–	795
2024 Q3	$169K	Buy	+13,410	New	+$173K	0.04%	575
2024 Q2	–	Sell	-45,295	Closed	-$217K	–	778
2024 Q1	$217K	Buy	+45,295	New	+$210K	0.06%	497

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

InceptionR's NVAX Position: Q4 2024 in Review

InceptionR sold out of Novavax (NVAX) in Q4 2024, closing a stake of 13,410 shares — an estimated $169K sold.

InceptionR first reported a position in NVAX in Q1 2024 and held it in 2 quarters. The position peaked at $217K in Q1 2024. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

InceptionR reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
InceptionR sold 13,410 Novavax shares in Q4 2024, an estimated $169K.
InceptionR first reported a position in Novavax in Q1 2024 and held it in 2 quarters.
InceptionR's Novavax position peaked at $217K in Q1 2024.
234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on InceptionR's 13F filing for Q4 2024, filed 6 Feb 2025.